Avidity Biosciences Inc

RNA

46.580USD

-2.000-4.12%

Close 08/29, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

87 / 690

Overall Ranking

199 / 4751

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 18 analysts

Buy

Current Rating

67.412

Target Price

+44.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 18.14% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.90M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 85.24.

Undervalued

The company’s latest PE is -13.09, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 141.72M shares, decreasing 2.35% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 10.67M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.95.

The company's current financial score is 4.89, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.57M, representing a year-over-year decrease of 55.60%, while its net profit experienced a year-over-year decrease of 68.14%.

Score

Industry at a Glance

Previous score

4.89

Change

0



Financials

2.17

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

0.82

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.14

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.06

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -13.43, which is -68.91% below the recent high of -4.18 and 22.86% above the recent low of -10.36.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 87/690

No Data

The company’s current earnings forecast score is 8.67, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Avidity Biosciences Inc is 68.00, with a high of 96.00 and a low of 52.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 9.63, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 52.46 and the support level at 39.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.52

Change

-0.25

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-08-29

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 117.38%, representing a quarter-over-quarter decrease of 0.50%. The largest institutional shareholder is PRFDX, holding a total of 10.67M shares, representing 8.29% of shares outstanding, with 9.37% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

15.29M

-5.36%

Janus Henderson Investors

11.43M

+62.01%

T. Rowe Price Associates, Inc.

Star Investors

11.21M

+2.65%

RTW Investments L.P.

8.75M

+10.26%

Wellington Management Company, LLP

9.68M

+19.47%

The Vanguard Group, Inc.

Star Investors

9.22M

-2.01%

BlackRock Institutional Trust Company, N.A.

8.40M

-0.26%

RA Capital Management, LP

6.30M

--

Avoro Capital Advisors LLC

7.63M

+1.67%

Bristol Myers Squibb

5.08M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.21, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.98. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Avidity Biosciences Inc

RNA

6.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Zoetis Inc

ZTS

7.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.